COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors

COVID-19 pathology is mainly associated to a pulmonary disease which sometimes might result in an uncontrollable storm related to inflammatory diseases which could be fatal. It is well known that phosphodiesterase enzyme type 5 inhibitors (PDE5Is), such as sildenafil, have been successfully develope...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Kuraishy, Hayder M., Al-Gareeb, Ali I., Al-Niemi, Marwa S., Al-Buhadily, Ali K., Al-Harchan, Nasser A., Lugnier, Claire
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883493/
https://www.ncbi.nlm.nih.gov/pubmed/33623736
http://dx.doi.org/10.4103/JMAU.JMAU_63_20
Descripción
Sumario:COVID-19 pathology is mainly associated to a pulmonary disease which sometimes might result in an uncontrollable storm related to inflammatory diseases which could be fatal. It is well known that phosphodiesterase enzyme type 5 inhibitors (PDE5Is), such as sildenafil, have been successfully developed for the treatment of pulmonary arterial hypertension; interestingly, more recently, it was shown that PDE5Is might be also anti-inflammatory. Therefore, it would be of interest to question about the use of PDE5Is to overcome the COVID-19 storm, as much as PDE5 is mainly present in the lung tissues and vessels.

Ejemplares similares